Targeting c-MET in the battle against advanced nonsmall-cell lung cancer

Current Opinion in Oncology

Volumn 25, Issue 2, 2013, Pages 130-136

  Landi, Lorenza ^a   Minuti, Gabriele ^a   D'Incecco, Armida ^a   Cappuzzo, Federico ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

HGF; MET; MET inhibition; nonsmall cell lung cancer

Indexed keywords

CABOZANTINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FICLATUZUMAB; FORETINIB; OA5D5; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TIVANTINIB; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER PROGNOSIS; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; INHIBITION KINETICS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SOLID TUMOR;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84873632444     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835daf37     Document Type: Review

References (66)

1. Sandler A, Gray R, Perry MC, et al. Paclitaxel carboplatin alone or with bevacizumab for nonsmall cell lung cancer. N Engl J Med 2006; 355:2542-2550.
2. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced nonsmall-cell lung cancer (flex): an open-label randomised phase III trial. Lancet 2009; 373:1525-1531.
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 2005; 353:123-132.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
5. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic nonsmall-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13:528-538.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
7. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-13311.
8. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012; 13:539-548.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
10. Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in nonsmall-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005; 23:3227-3234.
11. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043.
12. Xu L, Kikuchi E, Xu C, et al. Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 2012; 72:3302-3311.
13. Kang JY, Dolled-Filhart M, Ocal IT, et al. Tissue microarray analysis of hepatocyte growth factor/met pathway components reveals a role for met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003; 63:1101-1105.
14. Tsao MS, Liu N, Chen JR, et al. Differential expression of met/hepatocyte growth factor receptor in subtypes of nonsmall cell lung cancer. Lung Cancer 1998; 20:1-16.
15. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997; 57:5391-5398.
16. Hara T, Ooi A, Kobayashi M, et al. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 1998; 78:1143-1153.
17. Miller CT, Lin L, Casper AM, et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006; 25:409-418.
18. Sawada K, Radjabi AR, Shinomiya N, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007; 67:1670-1679.
19. Nagy J, Curry GW, Hillan KJ, et al. Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg Oncol 1996; 5:15-21.
20. Lubensky IA, Schmidt L, Zhuang Z, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999; 155:517-526.
21. Ueki T, Fujimoto J, Suzuki T, et al. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 1997; 25:619-623.
22. Blumenschein Jr GR, Mills GB, Gonzales-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 2012; 30:3287-3296.
23. Appleman L. MET signaling pathway: a rational target for cancer therapy. J Clin Oncol 2011; 29:4837-4838.
24. Boccaccio C. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006; 6:637-645.
25. Ichimura E, Maeshima A, Nakajima T, et al. Expression of c-met/HGF receptor in human nonsmall cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996; 87:1063-1069.
26. Cipriani N, Abidoye O, Vokes E, et al. MET as a target for treatment of chest tumors. Lung Cancer 2009; 63:169-179.
27. Garcia S, Dalè s JP, Charafe-Jauffret E, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 2007; 38:830-841.
28. Takanami I, Tanana F, Hashizume T, Kikuchi K, et al. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology 1996; 53:392-397.
29. Bean J, Brennan C, Shih J, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104:20932-20937.
30. Chen H, Mok T, Chen Z, et al. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese nonsmall cell lung cancer. Pathol Oncol Res 2009; 15:651-658.
31. Okuda K, Sasaki H, Yukiue H, et al. Met gene copy number predicts the prognosis for completely resected nonsmall cell lung cancer. Cancer Sci 2008; 99:2280-2285.
32. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected nonsmall-cell lung cancer patients. J Clin Oncol 2009; 27:1667-1674.
33. Toschi L, Cappuzzo F. Clinical implications of MET gene copy number in lung cancer. Future Oncol 2010; 6:239-247.
34. Ma P, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63:6272-6281.
35. Krishnaswamy S, Kanteti R, Duke-Cohan JS, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009; 15:5714-5723.
36. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006; 66:283-289.
37. Abounader R, Ranganathan S, Lal B, et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-Met expression. J Natl Cancer Inst 1999; 91:1548-1556.
38. Kaji M, Yonemura Y, Harada S, et al. Participation of c-Met in the progression of human gastric cancers: antic-Met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. Cancer Gene Ther 1996; 3:393-404.
39. Jiang WG, Grimshaw D, Lane J, et al. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-Met and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res 2001; 7:2555-2562.
40. Stabile LP, Lyker JS, Huang L, et al. Inhibition of human nonsmall cell lung tumors by a c-Metantisense/U6 expression plasmid strategy. Gene Ther 2004; 11:325-335.
41. Davies G, Watkins G, Mason MD, et al. Targeting the HGF/SF receptor c-Met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells. Prostate 2004; 60:317-324.
42. Canadas I, Rojo F, Arum-Ura M, et al. C-MET as a new therapeutic target for the development of novel anticancer drugs. Clin Transl Oncol 2010; 12:253-260.
43. Date K, Matsumoto K, Shimura H, et al. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997; 420:1-6.
44. Kuba K, Matsumoto K, Date K, et al. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000; 60:6737-6743.
45. Matsumoto K, Nakamura T, et al. Nk4 gene therapy targeting HGF-met and angiogenesis. Front Biosci 2008; 13:1943-1951.
46. Mazzone M, Basilico C, Cavassa S, et al. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest 2004; 114:1418-1432.
47. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006; 66: 1721-1729.
48. Kim KJ, Wang L, Su YC, et al. Systemic antihepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006; 12:1292-1298.
49. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human antihepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87mg cells and xenografts. Clin Cancer Res 2007; 13:6735-6742.
50. Wen PY, Schiff D, Cloughesy TF, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 2011; 13:437-446.
51. Tan E, Park K, Lim WT, et al. Phase Ib study of ficlatuzumab (formerly AV-299), an antihepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol 2011; 29(Suppl. 15):493s(abstr. 7571).
52. Mok, Park K, Geater SL, et al. A randomized phase 2 study with exploratory biomarker analysis of ficlatuzumab, a humanized hepatocyte growth factor (HGF) inhibitory monoclonal antibody, in combination with gefitinib versus gefitinib alone in Asian patients with lung adenocarcinoma. Ann Oncol 2012; 23(Suppl. 10):abstr.
53. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed antic-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12:6144-6152.
54. Jin H, Yang R, Zheng Z, et al. Metmab, the one-armed 5d5 antic-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68:4360-4368.
55. Tseng JR, Kang KW, Dandekar M, et al. Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by18FFDG small-animal PET. J Nucl Med 2008; 49:129-134.
56. Petrelli A, Circosta P, Granziero L, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci USA 2006; 103:5090-5095.
57. Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011; 29(Suppl.):abstr. 7505.
58. Sai-Hong IO. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond. Drug Des Dev Ther 2011; 5:471-485.
59. Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009; 27(15 Suppl.):abstr. 3509.
60. Kwak EL, Bang Y-J, Camidge R, et al. Anaplastic lymphoma kinase inhibition in nonsmall cell lung cancer. N Engl J Med 2010; 363:1693-1703.
61. Eder JP, VandeWoude GF,Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15:2207-2214.
62. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10:2298-2308.
63. Kollmannsberger CK, Hurwitz H, Vlahovic G, et al. Phase I study of daily administration of GCD265 to patients with advanced malignancies (study 265-101). J Clin Oncol 2009; 27:(Suppl.; abstr. e14525).
64. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3:75ra26.
65. Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in nonsmall cell lung cancer patients. Ann Oncol 2009; 20:298-304.
66. Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated nonsmall-cell lung cancer. J Clin Oncol 2011; 29:3307-3315.